Mechanism
T-cell-mediated CNS inflammation, microglial activation, or autoinflammatory cytokine excess can lower seizure threshold, disrupt sleep-state spike-wave dynamics, and respond to corticosteroids without producing classical pleocytosis or oligoclonal bands. Serum Th1/Th17 cytokine elevation in absence of infection is a compatible peripheral signature.
How This Maps To Levi's Case
Serum sIL-2R, IFN-gamma, TNF-alpha, IL-17, and IL-13 all elevated on April 6, 2026 with normal WBC and undetectable hsCRP is a real peripheral inflammatory pattern. Dramatic electrographic and clinical response to a 3-day IV methylprednisolone pulse is consistent. January 16, 2026 leukocytosis with left shift preceding the acute regression fits a permissive inflammatory trigger.
Supporting Evidence
Abnormal Th1/Th17-weighted serum cytokine panel April 6, 2026.
sIL-2R 1031, IFN-gamma 12.7, TNF-alpha 13.3, IL-17 1.8, IL-13 4.0 together at a non-infected timepoint is a real pattern.
Near-total electrographic resolution of spike-wave burden within two weeks of a 3-day IV methylprednisolone pulse.
Strong steroid responsiveness is consistent with an inflammatory contribution, although not specific to it.
January 16, 2026 leukocytosis WBC 24.2 with neutrophilia and immature granulocytes, fully resolved by April 6.
Temporally upstream of the acute regression escalation; a transient inflammatory trigger is a plausible permissive factor.
Against / Caveats
No CSF pleocytosis (TNC 2), normal CSF protein, negative CSF and serum oligoclonal bands.
Argues against overt CNS humoral autoimmunity; does not rule out compartmentalized cell-mediated inflammation.
Comprehensive serum autoimmune encephalitis antibody panel (14 antibodies) negative on March 23, 2026.
Rules out classical antibody-positive AE; does not rule out seronegative / cell-mediated AE.
hsCRP undetectable on April 6, 2026.
Argues against systemic acute inflammation at that snapshot. Not definitive for a tissue-compartmentalized process.
If This Is Confirmed
- Justifies sustained immunomodulation (repeated IV methylprednisolone pulses, IVIG, possibly rituximab or tocilizumab in refractory cases).
- Changes posture around steroid taper aggressiveness.
- Does not replace the need for the genetic workup.
Key Unknowns
- CSF cytokine panel (not sent on April 7 LP).
- CSF autoimmune encephalitis antibody panel (not sent on April 7 LP).
- CSF neopterin.
- Repeat serum cytokine panel off steroids.
- Was an infectious source identified for the January 16 event?
What Would Move Confidence
- Repeat LP with CSF cytokines (Th1/Th17 panel), CSF AE panel, CSF neopterin - timed with steroid taper.
- Repeat serum cytokine panel off steroids.
- Review January 16, 2026 clinical chart for a documented illness source.
- Pediatric neuroimmunology consultation.
Key References
Synthesis memo (corpus-grounded reasoning)
Literature-pass memo (external evidence)
Cellucci 2020 - Clinical approach to pediatric autoimmune encephalitis
Titulaer 2024 - Seronegative autoimmune encephalitis in children
Armangué 2024 - Pediatric AE differential diagnosis and algorithm comparison
Mimics of Autoimmune Encephalitis - Neurol Neuroimmunol Neuroinflam 2023
2025 CSF cytokine study in ESES
Kothur 2019 - CSF cytokines in FIRES and febrile SE
Th17 in neurological disorders - Frontiers 2022 review
IL-17A / Th17 in autoimmune neurological disease - Frontiers 2025 review
Glucocorticoids promote intrinsic human TH17 differentiation - JACI 2018
Likelihood Change Log
Last reassessed Apr 19, 2026 because Reassessed 2026-04-19 against the HPA-axis / hypothalamic literature pass. Cross-cutting positive signal - Kessi 2019 explicitly connects elevated IL-6 to CSWS pathogenesis, and IL-6 is a canonical HPA-axis activator (Papanicolaou 1998). The neuroinflammation theory and the new hypothalamic-hpa-axis-contribution theory therefore converge rather than compete - if serum or CSF IL-6 is elevated in Levi (currently unmeasured), both branches gain support from the same finding. This strengthens the priority of adding IL-6 to the next cytokine panel and reinforces (does not change) the rank. Prior 2026-04-18 Viswanathan reassessment was no-op (genetic cohort, out of scope for inflammatory mechanism). Prior 2026-04-17 DNMT3A pass was also no-op for the same structural reason.
HPA-axis / hypothalamic reassessment (user-requested targeted literature pass).
~20%. Cross-cutting positive signal that strengthens (does not change) the rank. Kessi 2019 implicates elevated IL-6 in CSWS pathogenesis specifically. IL-6 is a canonical HPA-axis activator (Papanicolaou 1998). The neuroinflammation theory and the new hypothalamic-hpa-axis-contribution theory therefore converge - if serum or CSF IL-6 is elevated in Levi (currently unmeasured), both branches gain support from the same finding rather than competing. Action item - ensure IL-6 is included on the next serum cytokine panel and on any CSF cytokine panel; this was previously implicit and is now explicitly justified. Holds at 20.
Viswanathan et al. 2024 DEE-SWAS etiology cohort (n=101).
~20%. Out of scope - Viswanathan is a genetic-etiology cohort and does not address inflammatory mechanisms of DEE-SWAS. The cytokine / steroid-response evidence base is independent. Holds.
DNMT3A / methylation-axis deep-dive (user-requested targeted literature pass).
~20%. The chromatinopathy / methylation literature does not address seronegative cell-mediated neuroinflammation and is not in scope for this theory. Key decisive test (CSF cytokine panel off steroids plus repeat serum cytokines) remains the highest-yield next step independently of methylation testing.
Initial differential population after PRs
~20%. Elevated because of (a) the serum Th1/Th17 pattern and (b) the dramatic steroid response, tempered by (c) clean CSF and (d) negative AE serology. Upper bound constrained by the missing CSF cytokine data.
Literature pass 2026-04-16 (broad) - external citations added.
~20%. Cellucci 2020 and Titulaer 2024 formalize pediatric seronegative AE as a real and distinct category in which classical AE serology is negative and CSF can be clean. The 2025 ESES CSF cytokine study documents an IL-1beta / TNF / IL-6 signature in some children with ESES, strengthening the rationale for a CSF cytokine panel. The JACI 2018 paper is a critical caveat - the April 6 serum Th17 elevation may partly reflect post-steroid TH17 skewing rather than purely disease-driven inflammation, so interpretation should wait for a repeat panel off steroids. Net likelihood is unchanged at 20 percent; the key decisive test (CSF cytokines + repeat serum cytokines off steroids) has not yet been done.